BioSpace News Archive

Kaye has been a leader for over 60 years in the Validation and Monitoring of critical process data. With its introduction of the Kaye Log -80 Vaccine Temperature Logger and KayeTrack Cloud Kaye has applied the same quality principles to ensure the validation and safety of the Cold Chain.

Exclusive license from MRC Laboratory of Molecular Biology of rights to enhanced version of MOGRIFY technology incorporating next-generation RNA sequencing data to enable more accurate transcription factor predictions and improve cell conversion efficacy

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, announced the establishment of its independent Board of Directors by the appointment of Björn Cochlovius, Ph.D., as Chairman of the Board, effective immediately.

NHS Greater Glasgow and Clyde Health Board, the largest NHS organization in Scotland and one of the largest in the UK, has joined the TriNetX global health research network to better leverage its extensive patient data and to promote its participation in clinical trials and research.

Brains Bioceutical Corp., One of the rare few EU-GMP Certified CBD API producers in the UK awarded a Schedule 1 Controlled Drug Licence by the UK Home Office, maintaining our industry leading advantage for Cannabinoid based medicines

- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial - - Conference Call and Webcast Today, December 17, 2020 at 8:30 am ET -

MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21

Sonnet BioTherapeutics Holdings, Inc. , a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30 th , 2020 and provided a business update.

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA ® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophageal Junction Cancer Application Based on Overall Survival and Progression-Free Survival Data Comparing KEYTRUDA Plus Chemotherapy to Chemotherapy Alone From Pivotal Phase 3 KEYNOTE-590 Trial

Horizon Therapeutics plc Announces Short-Term TEPEZZA ® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production